Mark A. Hillman
Hillman Value Fund
Mark A. Hillman Biogen Inc stake
total: 75
Hillman Value Fund BIIB trades
- Total transactions:
- 12
- New positions:
- 1
- Added:
- 6
- Reduced:
- 5
- Held since:
- 2020 Q1
- Held for:
- 25 quarters
- Latest activity:
- 2025 Q4
According to 2026 Q1 report, Mark A. Hillman holds 14,100 Biogen Inc (BIIB) shares with a market value of roughly $2.58M accounting for 3.11% of the overall portfolio. To date, the estimated cost basis is nearly $243 for "buy" trades and estimated average "sell" price is $191. Hillman Value Fund first purchased BIIB in 2020 Q1, initially acquiring 10,000 shares. Since the initial investment in Biogen Inc (BIIB), Hillman Value Fund has made 11 more transactions.
When did Mark A. Hillman buy Biogen Inc (BIIB)?
Mark A. Hillman first invested in Biogen Inc (BIIB) in 2020 Q1 at the reported quarter-end price of $316.38 per share.
What's the cost basis of Hillman Value Fund's BIIB stake?
The estimated cost basis for Biogen Inc (BIIB) stake is around $243.00 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $243.00
- Weighted AVG sell price:
- $191.00
Mark A. Hillman's historical trades in Biogen Inc
12 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2025 Q4
|
2.65%
|
14,100
|
$175.99
|
$2,481,459
|
-27.69% (-5,400)
|
-0.9%
|
|
2025 Q3
|
2.60%
|
19,500
|
$140.08
|
$2,731,560
|
-17.37% (-4,100)
|
-0.48%
|
|
2025 Q2
|
2.50%
|
23,600
|
$125.59
|
$2,963,924
|
-8.53% (-2,200)
|
-0.19%
|
|
2025 Q1
|
2.48%
|
25,800
|
$136.84
|
$3,530,472
|
-21.82% (-7,200)
|
-0.47%
|
|
2024 Q4
|
2.39%
|
33,000
|
$152.92
|
$5,046,360
|
+35.25% (+8,600)
|
+0.62%
|
|
2024 Q1
|
2.17%
|
24,400
|
$215.63
|
$5,261,372
|
+0.57% (+139)
|
+0.01%
|
|
2023 Q3
|
2.99%
|
24,261
|
$257.01
|
$6,235,320
|
+32.86% (+6,000)
|
+0.74%
|
|
2022 Q3
|
2.71%
|
18,261
|
$267.00
|
$4,875,687
|
-37.25% (-10,839)
|
-1.39%
|
|
2022 Q1
|
2.49%
|
29,100
|
$210.60
|
$6,128,460
|
+59.89% (+10,900)
|
+0.93%
|
|
2021 Q1
|
2.95%
|
18,200
|
$279.75
|
$5,091,450
|
+37.88% (+5,000)
|
+0.81%
|
|
2020 Q3
|
3.61%
|
$283.68
|
+32.00% (+3,200)
|
|||
|
2020 Q1
|
4.41%
|
$316.38
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.